TWi Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Cutting-Edge Clinical Development

Leading Biopharma Company Adopts Medidata Technology to Bring Operational Efficiencies and Greater Speed to Innovative Clinical Study on Metabolic Disorders

NEW YORK--()--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by TWi Biotechnology, Inc. A top biopharmaceutical company based in Taiwan, TWi Biotechnology selected the Medidata Clinical Cloud® to enhance the speed, quality and productivity of its novel clinical study on metabolic disorders.

“The Medidata platform has been broadly adopted globally and using it allows TWi to be more efficient, while ensuring investigative sites and clinical research coordinators are familiar and engaged with the technology,” said Dr. Calvin Chen, TWi Biotechnology’s president. “We’re pleased to be collaborating with Medidata as we work to address unmet medical needs and continue to provide innovative, high-quality treatments to patients worldwide.”

TWi Biotechnology is focused on developing innovative new therapies for unmet medical needs in the areas of metabolism, orphan diseases and dermatology. To optimize a Phase-II study on metabolic disorders, TWi Biotechnology is implementing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®) and medical coding (Medidata Coder®). In addition to enhancing productivity through real-time data entry, Medidata’s technology solutions are providing TWi Biotechnology with better clinical trial oversight that leads to earlier, more informed decision-making opportunities.

“Emerging markets in Asia hold great promise for future growth in the life sciences industry,” said Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region. “We’re thrilled that TWi has selected Medidata’s technology to power their important research, providing us with the opportunity to contribute to drug development activities in Taiwan—and across Asia—that have the potential to advance new therapies in areas of significant unmet need.”

About TWi Biotechnology, Inc.

TWi Biotechnology, Inc., a fully owned subsidiary of TWi Pharmaceuticals, Inc., is a leading clinical stages biopharmaceutical company based in Taipei, Taiwan, specializing in the development of innovative new drugs for unmet medical needs, especially in the diseases associated with innate immunity. The company is building its product pipeline through in-licensing and internal research. TWi Biotechnology's product development pipeline includes three drug candidates for treating type-II diabetes, arthritis, and immunodermatology diseases.

About Medidata

Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Contacts

Investors:
Medidata Solutions
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media – Americas & EMEA:
Medidata Solutions
Nicole Pariser, 212-659-1069
npariser@mdsol.com
or
Media – APAC:
Medidata Solutions
Masako Ishida, +81 3-4588 0400
mishida@mdsol.com

Contacts

Investors:
Medidata Solutions
Hulus Alpay, 212-419-1025
halpay@mdsol.com
or
Media – Americas & EMEA:
Medidata Solutions
Nicole Pariser, 212-659-1069
npariser@mdsol.com
or
Media – APAC:
Medidata Solutions
Masako Ishida, +81 3-4588 0400
mishida@mdsol.com